#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Cingulate	_
1-2	10-16	cortex	_
1-3	17-27	functional	_
1-4	28-40	connectivity	_
1-5	41-49	predicts	_
1-6	50-56	future	_
1-7	57-64	relapse	_
1-8	65-67	in	_
1-9	68-75	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-10	76-85	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-11	86-97	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-12	98-105	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-13	106-116	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-14	117-119	is	_
1-15	120-121	a	_
1-16	122-129	chronic	_
1-17	130-139	relapsing	_
1-18	140-147	illness	_
1-19	148-149	.	_

2-1	150-157	Alcohol	_
2-2	158-161	and	_
2-3	162-168	stress	_
2-4	169-173	cues	_
2-5	174-178	have	_
2-6	179-191	consistently	_
2-7	192-196	been	_
2-8	197-202	shown	_
2-9	203-205	to	_
2-10	206-214	increase	_
2-11	215-222	craving	_
2-12	223-226	and	_
2-13	227-234	relapse	_
2-14	235-239	risk	_
2-15	240-242	in	_
2-16	243-253	recovering	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
2-17	254-261	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
2-18	262-271	dependent	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
2-19	272-273	(	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
2-20	274-277	AUD	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
2-21	278-279	)	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
2-22	280-288	patients	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
2-23	289-290	.	_

3-1	291-298	However	_
3-2	299-300	,	_
3-3	301-312	differences	_
3-4	313-315	in	_
3-5	316-326	functional	_
3-6	327-339	connectivity	_
3-7	340-342	in	_
3-8	343-351	response	_
3-9	352-354	to	_
3-10	355-360	these	_
3-11	361-365	cues	_
3-12	366-370	have	_
3-13	371-374	not	_
3-14	375-379	been	_
3-15	380-387	studied	_
3-16	388-393	using	_
3-17	394-405	data-driven	_
3-18	406-416	approaches	_
3-19	417-418	.	_

4-1	419-423	Here	_
4-2	424-425	,	_
4-3	426-436	voxel-wise	_
4-4	437-449	connectivity	_
4-5	450-452	is	_
4-6	453-457	used	_
4-7	458-460	in	_
4-8	461-462	a	_
4-9	463-474	whole-brain	_
4-10	475-488	investigation	_
4-11	489-491	of	_
4-12	492-502	functional	_
4-13	503-515	connectivity	_
4-14	516-527	differences	_
4-15	528-538	associated	_
4-16	539-543	with	_
4-17	544-551	alcohol	_
4-18	552-555	and	_
4-19	556-562	stress	_
4-20	563-567	cues	_
4-21	568-571	and	_
4-22	572-574	to	_
4-23	575-582	examine	_
4-24	583-590	whether	_
4-25	591-596	these	_
4-26	597-608	differences	_
4-27	609-612	are	_
4-28	613-620	related	_
4-29	621-623	to	_
4-30	624-634	subsequent	_
4-31	635-642	relapse	_
4-32	643-644	.	_

5-1	645-647	In	_
5-2	648-653	Study	_
5-3	654-655	1	_
5-4	656-657	,	_
5-5	658-660	45	_
5-6	661-662	,	_
5-7	663-665	4-	_
5-8	666-668	to	_
5-9	669-675	8-week	_
5-10	676-685	abstinent	_
5-11	686-687	,	_
5-12	688-698	recovering	http://maven.renci.org/NeuroBridge/neurobridge#FluidAttenuatedInversionRecoveryImaging
5-13	699-702	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-14	703-711	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-15	712-721	underwent	_
5-16	722-732	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-17	733-741	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-18	742-751	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-19	752-759	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-20	760-766	during	_
5-21	767-781	individualized	_
5-22	782-789	imagery	_
5-23	790-792	of	_
5-24	793-800	alcohol	_
5-25	801-802	,	_
5-26	803-809	stress	_
5-27	810-811	,	_
5-28	812-815	and	_
5-29	816-823	neutral	_
5-30	824-828	cues	_
5-31	829-830	.	_

6-1	831-838	Relapse	_
6-2	839-847	measures	_
6-3	848-852	were	_
6-4	853-862	collected	_
6-5	863-876	prospectively	_
6-6	877-880	for	_
6-7	881-883	90	_
6-8	884-888	days	_
6-9	889-903	post-discharge	_
6-10	904-908	from	_
6-11	909-918	inpatient	_
6-12	919-928	treatment	_
6-13	929-930	.	_

7-1	931-934	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-2	935-943	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-3	944-950	showed	_
7-4	951-958	blunted	_
7-5	959-967	anterior	_
7-6	968-969	(	_
7-7	970-973	ACC	_
7-8	974-975	)	_
7-9	976-977	,	_
7-10	978-981	mid	_
7-11	982-983	(	_
7-12	984-987	MCC	_
7-13	988-989	)	_
7-14	990-993	and	_
7-15	994-1003	posterior	_
7-16	1004-1013	cingulate	_
7-17	1014-1020	cortex	_
7-18	1021-1022	(	_
7-19	1023-1026	PCC	_
7-20	1027-1028	)	_
7-21	1029-1030	,	_
7-22	1031-1041	voxel-wise	_
7-23	1042-1054	connectivity	_
7-24	1055-1064	responses	_
7-25	1065-1067	to	_
7-26	1068-1074	stress	_
7-27	1075-1083	compared	_
7-28	1084-1086	to	_
7-29	1087-1094	neutral	_
7-30	1095-1099	cues	_
7-31	1100-1103	and	_
7-32	1104-1111	blunted	_
7-33	1112-1115	PCC	_
7-34	1116-1124	response	_
7-35	1125-1127	to	_
7-36	1128-1135	alcohol	_
7-37	1136-1144	compared	_
7-38	1145-1147	to	_
7-39	1148-1155	neutral	_
7-40	1156-1160	cues	_
7-41	1161-1162	.	_

8-1	1163-1168	Using	_
8-2	1169-1172	Cox	_
8-3	1173-1185	proportional	_
8-4	1186-1192	hazard	_
8-5	1193-1203	regression	_
8-6	1204-1205	,	_
8-7	1206-1212	weaker	_
8-8	1213-1225	connectivity	_
8-9	1226-1228	in	_
8-10	1229-1232	ACC	_
8-11	1233-1236	and	_
8-12	1237-1240	MCC	_
8-13	1241-1247	during	_
8-14	1248-1255	neutral	_
8-15	1256-1264	exposure	_
8-16	1265-1268	was	_
8-17	1269-1279	associated	_
8-18	1280-1284	with	_
8-19	1285-1291	longer	_
8-20	1292-1296	time	_
8-21	1297-1299	to	_
8-22	1300-1307	relapse	_
8-23	1308-1309	(	_
8-24	1310-1316	better	_
8-25	1317-1325	recovery	_
8-26	1326-1333	outcome	_
8-27	1334-1335	)	_
8-28	1336-1337	.	_

9-1	1338-1347	Similarly	_
9-2	1348-1349	,	_
9-3	1350-1357	greater	_
9-4	1358-1370	connectivity	_
9-5	1371-1373	in	_
9-6	1374-1377	PCC	_
9-7	1378-1384	during	_
9-8	1385-1396	alcohol-cue	_
9-9	1397-1405	compared	_
9-10	1406-1408	to	_
9-11	1409-1415	stress	_
9-12	1416-1419	cue	_
9-13	1420-1423	was	_
9-14	1424-1434	associated	_
9-15	1435-1439	with	_
9-16	1440-1446	longer	_
9-17	1447-1451	time	_
9-18	1452-1454	to	_
9-19	1455-1462	relapse	_
9-20	1463-1464	.	_

10-1	1465-1467	In	_
10-2	1468-1473	Study	_
10-3	1474-1475	2	_
10-4	1476-1477	,	_
10-5	1478-1479	a	_
10-6	1480-1489	sub-group	_
10-7	1490-1492	of	_
10-8	1493-1495	30	_
10-9	1496-1499	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-10	1500-1508	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-11	1509-1513	were	_
10-12	1514-1537	demographically-matched	_
10-13	1538-1540	to	_
10-14	1541-1543	30	_
10-15	1544-1551	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-16	1552-1559	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-17	1560-1561	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-18	1562-1564	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-19	1565-1566	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-20	1567-1579	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-21	1580-1583	for	_
10-22	1584-1589	group	_
10-23	1590-1601	comparisons	_
10-24	1602-1603	.	_

11-1	1604-1607	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
11-2	1608-1616	compared	_
11-3	1617-1619	to	_
11-4	1620-1622	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-5	1623-1635	participants	_
11-6	1636-1642	showed	_
11-7	1643-1650	reduced	_
11-8	1651-1660	cingulate	_
11-9	1661-1673	connectivity	_
11-10	1674-1680	during	_
11-11	1681-1688	alcohol	_
11-12	1689-1692	and	_
11-13	1693-1699	stress	_
11-14	1700-1704	cues	_
11-15	1705-1706	.	_

12-1	1707-1712	Using	_
12-2	1713-1718	novel	_
12-3	1719-1730	data-driven	_
12-4	1731-1741	approaches	_
12-5	1742-1743	,	_
12-6	1744-1747	the	_
12-7	1748-1757	cingulate	_
12-8	1758-1764	cortex	_
12-9	1765-1772	emerged	_
12-10	1773-1775	as	_
12-11	1776-1777	a	_
12-12	1778-1781	key	_
12-13	1782-1788	region	_
12-14	1789-1791	in	_
12-15	1792-1795	the	_
12-16	1796-1806	disruption	_
12-17	1807-1809	of	_
12-18	1810-1820	functional	_
12-19	1821-1833	connectivity	_
12-20	1834-1840	during	_
12-21	1841-1848	alcohol	_
12-22	1849-1852	and	_
12-23	1853-1863	stress-cue	_
12-24	1864-1874	processing	_
12-25	1875-1877	in	_
12-26	1878-1881	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-27	1882-1890	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-28	1891-1894	and	_
12-29	1895-1897	as	_
12-30	1898-1899	a	_
12-31	1900-1906	marker	_
12-32	1907-1909	of	_
12-33	1910-1920	subsequent	_
12-34	1921-1928	alcohol	_
12-35	1929-1936	relapse	_
12-36	1937-1938	.	_

13-1	1939-1949	Highlights	_
13-2	1950-1953	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-3	1954-1962	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-4	1963-1969	showed	_
13-5	1970-1977	blunted	_
13-6	1978-1987	cingulate	_
13-7	1988-2000	connectivity	_
13-8	2001-2003	to	_
13-9	2004-2011	alcohol	_
13-10	2012-2015	and	_
13-11	2016-2022	stress	_
13-12	2023-2027	cues	_
13-13	2028-2029	.	_

14-1	2030-2039	Cingulate	_
14-2	2040-2052	connectivity	_
14-3	2053-2062	predicted	_
14-4	2063-2067	time	_
14-5	2068-2070	to	_
14-6	2071-2078	relapse	_
14-7	2079-2081	in	_
14-8	2082-2085	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-9	2086-2094	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-10	2095-2096	.	_

15-1	2097-2104	Greater	_
15-2	2105-2108	PCC	_
15-3	2109-2121	connectivity	_
15-4	2122-2128	during	_
15-5	2129-2136	alcohol	_
15-6	2137-2141	cues	_
15-7	2142-2151	predicted	_
15-8	2152-2158	longer	_
15-9	2159-2163	time	_
15-10	2164-2166	to	_
15-11	2167-2174	relapse	_
15-12	2175-2176	.	_

16-1	2177-2180	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
16-2	2181-2184	vs.	_
16-3	2185-2187	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-4	2188-2196	subjects	_
16-5	2197-2203	showed	_
16-6	2204-2208	less	_
16-7	2209-2218	cingulate	_
16-8	2219-2231	connectivity	_
16-9	2232-2234	to	_
16-10	2235-2242	alcohol	_
16-11	2243-2246	and	_
16-12	2247-2253	stress	_
16-13	2254-2258	cues	_
16-14	2259-2260	.	_

17-1	2261-2264	The	_
17-2	2265-2274	cingulate	_
17-3	2275-2281	cortex	_
17-4	2282-2289	emerged	_
17-5	2290-2292	as	_
17-6	2293-2294	a	_
17-7	2295-2301	marker	_
17-8	2302-2304	of	_
17-9	2305-2315	subsequent	_
17-10	2316-2323	alcohol	_
17-11	2324-2331	relapse	_
17-12	2332-2333	.	_

18-1	2334-2343	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-2	2344-2347	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-3	2348-2355	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-4	2356-2359	All	_
18-5	2360-2365	study	_
18-6	2366-2376	procedures	_
18-7	2377-2381	were	_
18-8	2382-2390	approved	_
18-9	2391-2393	by	_
18-10	2394-2397	the	_
18-11	2398-2403	Human	_
18-12	2404-2417	Investigation	_
18-13	2418-2427	Committee	_
18-14	2428-2430	of	_
18-15	2431-2434	the	_
18-16	2435-2439	Yale	_
18-17	2440-2450	University	_
18-18	2451-2457	School	_
18-19	2458-2460	of	_
18-20	2461-2469	Medicine	_
18-21	2470-2471	.	_

19-1	2472-2475	All	_
19-2	2476-2488	participants	_
19-3	2489-2495	signed	_
19-4	2496-2497	a	_
19-5	2498-2505	written	_
19-6	2506-2514	informed	_
19-7	2515-2522	consent	_
19-8	2523-2527	form	_
19-9	2528-2529	.	_

20-1	2530-2542	Participants	_
20-2	2543-2548	Study	_
20-3	2549-2550	1	_
20-4	2551-2552	:	_
20-5	2553-2563	Forty-five	_
20-6	2564-2574	recovering	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-7	2575-2578	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-8	2579-2587	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-9	2588-2589	(	_
20-10	2590-2592	10	_
20-11	2593-2599	female	_
20-12	2600-2601	,	_
20-13	2602-2606	aged	_
20-14	2607-2612	18–50	_
20-15	2613-2614	,	_
20-16	2615-2616	M	_
20-17	2617-2618	=	_
20-18	2619-2623	37.7	_
20-19	2624-2625	)	_
20-20	2626-2629	and	_
20-21	2630-2632	30	_
20-22	2633-2640	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
20-23	2641-2648	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
20-24	2649-2660	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
20-25	2661-2662	(	_
20-26	2663-2664	9	_
20-27	2665-2671	female	_
20-28	2672-2673	,	_
20-29	2674-2678	aged	_
20-30	2679-2684	18–50	_
20-31	2685-2686	,	_
20-32	2687-2688	M	_
20-33	2689-2690	=	_
20-34	2691-2695	34.5	_
20-35	2696-2697	)	_
20-36	2698-2710	participated	_
20-37	2711-2713	in	_
20-38	2714-2718	this	_
20-39	2719-2724	study	_
20-40	2725-2726	.	_

21-1	2727-2737	Task-based	_
21-2	2738-2742	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
21-3	2743-2750	results	_
21-4	2751-2753	on	_
21-5	2754-2758	this	_
21-6	2759-2765	sample	_
21-7	2766-2769	and	_
21-8	2770-2774	full	_
21-9	2775-2782	details	_
21-10	2783-2785	on	_
21-11	2786-2789	the	_
21-12	2790-2802	participants	_
21-13	2803-2804	,	_
21-14	2805-2812	imagery	_
21-15	2813-2819	method	_
21-16	2820-2823	and	_
21-17	2824-2834	validation	_
21-18	2835-2836	,	_
21-19	2837-2840	and	_
21-20	2841-2848	relapse	_
21-21	2849-2857	measures	_
21-22	2858-2862	were	_
21-23	2863-2873	previously	_
21-24	2874-2883	published	_
21-25	2884-2886	in	_
21-26	2887-2888	.	_

22-1	2889-2892	All	_
22-2	2893-2896	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-3	2897-2905	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-4	2906-2909	had	_
22-5	2910-2911	a	_
22-6	2912-2919	current	_
22-7	2920-2929	diagnosis	_
22-8	2930-2932	of	_
22-9	2933-2940	alcohol	_
22-10	2941-2951	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
22-11	2952-2954	as	_
22-12	2955-2965	determined	_
22-13	2966-2968	by	_
22-14	2969-2970	a	_
22-15	2971-2981	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-16	2982-2990	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-17	2991-3000	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-18	3001-3004	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-19	3005-3011	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-20	3012-3013	,	_
22-21	3014-3017	and	_
22-22	3018-3027	abstained	_
22-23	3028-3032	from	_
22-24	3033-3040	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
22-25	3041-3044	for	_
22-26	3045-3046	4	_
22-27	3047-3049	to	_
22-28	3050-3051	6	_
22-29	3052-3057	weeks	_
22-30	3058-3059	(	_
22-31	3060-3064	mean	_
22-32	3065-3066	=	_
22-33	3067-3069	34	_
22-34	3070-3074	days	_
22-35	3075-3076	,	_
22-36	3077-3079	SE	_
22-37	3080-3081	=	_
22-38	3082-3086	1.14	_
22-39	3087-3088	)	_
22-40	3089-3094	while	_
22-41	3095-3103	actively	_
22-42	3104-3111	engaged	_
22-43	3112-3114	in	_
22-44	3115-3124	inpatient	_
22-45	3125-3144	non-pharmacological	_
22-46	3145-3154	substance	_
22-47	3155-3160	abuse	_
22-48	3161-3170	treatment	_
22-49	3171-3172	.	_

23-1	3173-3184	Demographic	_
23-2	3185-3192	details	_
23-3	3193-3196	are	_
23-4	3197-3206	presented	_
23-5	3207-3209	in	_
23-6	3210-3215	Table	_
23-7	3216-3218	S1	_
23-8	3219-3220	.	_

24-1	3221-3234	Tobacco-using	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
24-2	3235-3238	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
24-3	3239-3247	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
24-4	3248-3252	were	_
24-5	3253-3260	allowed	_
24-6	3261-3263	to	_
24-7	3264-3269	smoke	_
24-8	3270-3275	prior	_
24-9	3276-3278	to	_
24-10	3279-3289	initiating	_
24-11	3290-3293	the	_
24-12	3294-3298	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
24-13	3299-3303	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
24-14	3304-3307	and	_
24-15	3308-3312	thus	_
24-16	3313-3314	,	_
24-17	3315-3319	were	_
24-18	3320-3323	not	_
24-19	3324-3332	nicotine	_
24-20	3333-3341	deprived	_
24-21	3342-3344	at	_
24-22	3345-3348	the	_
24-23	3349-3353	time	_
24-24	3354-3356	of	_
24-25	3357-3361	scan	_
24-26	3362-3363	.	_

25-1	3364-3372	Patients	_
25-2	3373-3377	were	_
25-3	3378-3385	scanned	_
25-4	3386-3388	in	_
25-5	3389-3393	week	_
25-6	3394-3395	5	_
25-7	3396-3398	of	_
25-8	3399-3408	treatment	_
25-9	3409-3412	and	_
25-10	3413-3417	were	_
25-11	3418-3428	discharged	_
25-12	3429-3436	shortly	_
25-13	3437-3442	after	_
25-14	3443-3446	and	_
25-15	3447-3455	referred	_
25-16	3456-3458	to	_
25-17	3459-3469	outpatient	_
25-18	3470-3479	treatment	_
25-19	3480-3483	for	_
25-20	3484-3493	aftercare	_
25-21	3494-3495	.	_

26-1	3496-3499	All	_
26-2	3500-3508	patients	_
26-3	3509-3513	were	_
26-4	3514-3525	followed-up	_
26-5	3526-3530	with	_
26-6	3531-3540	in-person	_
26-7	3541-3551	interviews	_
26-8	3552-3561	conducted	_
26-9	3562-3564	at	_
26-10	3565-3567	14	_
26-11	3568-3569	,	_
26-12	3570-3572	30	_
26-13	3573-3574	,	_
26-14	3575-3578	and	_
26-15	3579-3581	90	_
26-16	3582-3586	days	_
26-17	3587-3601	post-discharge	_
26-18	3602-3604	to	_
26-19	3605-3613	evaluate	_
26-20	3614-3621	relapse	_
26-21	3622-3630	outcomes	_
26-22	3631-3636	using	_
26-23	3637-3642	urine	_
26-24	3643-3646	and	_
26-25	3647-3659	breathalyzer	_
26-26	3660-3667	samples	_
26-27	3668-3671	and	_
26-28	3672-3675	the	_
26-29	3676-3680	Form	_
26-30	3681-3683	90	_
26-31	3684-3693	Substance	_
26-32	3694-3697	Use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
26-33	3698-3706	Calendar	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
26-34	3707-3712	based	_
26-35	3713-3715	on	_
26-36	3716-3719	the	_
26-37	3720-3728	timeline	_
26-38	3729-3740	follow-back	_
26-39	3741-3747	method	_
26-40	3748-3749	.	_

27-1	3750-3755	Study	_
27-2	3756-3757	2	_
27-3	3758-3759	:	_
27-4	3760-3763	For	_
27-5	3764-3769	group	_
27-6	3770-3781	comparisons	_
27-7	3782-3783	,	_
27-8	3784-3786	30	_
27-9	3787-3789	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
27-10	3790-3802	participants	_
27-11	3803-3807	were	_
27-12	3808-3831	demographically-matched	_
27-13	3832-3834	to	_
27-14	3835-3837	30	_
27-15	3838-3839	(	_
27-16	3840-3841	8	_
27-17	3842-3848	female	_
27-18	3849-3850	,	_
27-19	3851-3855	aged	_
27-20	3856-3861	18–50	_
27-21	3862-3863	,	_
27-22	3864-3865	M	_
27-23	3866-3867	=	_
27-24	3868-3872	36.0	_
27-25	3873-3874	)	_
27-26	3875-3877	of	_
27-27	3878-3881	the	_
27-28	3882-3884	45	_
27-29	3885-3888	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
27-30	3889-3897	patients	_
27-31	3898-3900	on	_
27-32	3901-3904	age	_
27-33	3905-3906	,	_
27-34	3907-3910	sex	_
27-35	3911-3912	,	_
27-36	3913-3915	IQ	_
27-37	3916-3917	,	_
27-38	3918-3921	and	_
27-39	3922-3930	lifetime	_
27-40	3931-3941	prevalence	_
27-41	3942-3944	of	_
27-42	3945-3956	psychiatric	_
27-43	3957-3966	disorders	_
27-44	3967-3973	except	_
27-45	3974-3977	for	_
27-46	3978-3985	alcohol	_
27-47	3986-3996	dependence	_
27-48	3997-4000	and	_
27-49	4001-4008	smoking	_
27-50	4009-4015	status	_
27-51	4016-4017	.	_

28-1	4018-4025	Smoking	_
28-2	4026-4032	status	_
28-3	4033-4036	was	_
28-4	4037-4045	included	_
28-5	4046-4048	as	_
28-6	4049-4050	a	_
28-7	4051-4060	covariate	_
28-8	4061-4063	in	_
28-9	4064-4067	the	_
28-10	4068-4073	group	_
28-11	4074-4082	analyses	_
28-12	4083-4084	.	_

29-1	4085-4087	We	_
29-2	4088-4093	chose	_
29-3	4094-4096	to	_
29-4	4097-4112	demographically	_
29-5	4113-4118	match	_
29-6	4119-4121	as	_
29-7	4122-4126	many	_
29-8	4127-4130	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
29-9	4131-4139	patients	_
29-10	4140-4142	as	_
29-11	4143-4151	possible	_
29-12	4152-4154	to	_
29-13	4155-4158	the	_
29-14	4159-4161	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-15	4162-4174	participants	_
29-16	4175-4182	instead	_
29-17	4183-4185	of	_
29-18	4186-4195	comparing	_
29-19	4196-4199	all	_
29-20	4200-4202	45	_
29-21	4203-4206	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
29-22	4207-4215	patients	_
29-23	4216-4218	to	_
29-24	4219-4221	HC	_
29-25	4222-4224	as	_
29-26	4225-4227	IQ	_
29-27	4228-4231	and	_
29-28	4232-4237	years	_
29-29	4238-4240	of	_
29-30	4241-4250	education	_
29-31	4251-4255	were	_
29-32	4256-4269	significantly	_
29-33	4270-4275	lower	_
29-34	4276-4278	in	_
29-35	4279-4282	the	_
29-36	4283-4287	full	_
29-37	4288-4291	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
29-38	4292-4297	group	_
29-39	4298-4299	.	_

30-1	4300-4308	Matching	_
30-2	4309-4316	allowed	_
30-3	4317-4319	us	_
30-4	4320-4322	to	_
30-5	4323-4331	minimize	_
30-6	4332-4336	this	_
30-7	4337-4346	potential	_
30-8	4347-4355	confound	_
30-9	4356-4357	,	_
30-10	4358-4360	as	_
30-11	4361-4364	the	_
30-12	4365-4368	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
30-13	4369-4377	subgroup	_
30-14	4378-4381	was	_
30-15	4382-4385	not	_
30-16	4386-4399	significantly	_
30-17	4400-4409	different	_
30-18	4410-4414	from	_
30-19	4415-4417	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
30-20	4418-4430	participants	_
30-21	4431-4433	in	_
30-22	4434-4441	several	_
30-23	4442-4454	demographics	_
30-24	4455-4464	including	_
30-25	4465-4468	age	_
30-26	4469-4470	,	_
30-27	4471-4474	sex	_
30-28	4475-4478	and	_
30-29	4479-4481	IQ	_
30-30	4482-4483	,	_
30-31	4484-4487	but	_
30-32	4488-4491	was	_
30-33	4492-4505	significantly	_
30-34	4506-4515	different	_
30-35	4516-4518	in	_
30-36	4519-4525	number	_
30-37	4526-4528	of	_
30-38	4529-4536	smokers	_
30-39	4537-4539	in	_
30-40	4540-4543	the	_
30-41	4544-4547	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
30-42	4548-4554	versus	_
30-43	4555-4558	the	_
30-44	4559-4561	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
30-45	4562-4567	group	_
30-46	4568-4569	(	_
30-47	4570-4573	See	_
30-48	4574-4579	Table	_
30-49	4580-4582	S1	_
30-50	4583-4584	)	_
30-51	4585-4586	.	_

31-1	4587-4594	Imagery	_
31-2	4595-4603	paradigm	_
31-3	4604-4607	All	_
31-4	4608-4620	participants	_
31-5	4621-4628	engaged	_
31-6	4629-4631	in	_
31-7	4632-4634	an	_
31-8	4635-4642	imagery	_
31-9	4643-4651	paradigm	_
31-10	4652-4660	composed	_
31-11	4661-4663	of	_
31-12	4664-4678	individualized	_
31-13	4679-4684	2-min	_
31-14	4685-4692	imagery	_
31-15	4693-4700	scripts	_
31-16	4701-4709	designed	_
31-17	4710-4712	to	_
31-18	4713-4720	provoke	_
31-19	4721-4727	either	_
31-20	4728-4735	alcohol	_
31-21	4736-4737	,	_
31-22	4738-4747	stressful	_
31-23	4748-4749	,	_
31-24	4750-4752	or	_
31-25	4753-4769	neutral/relaxing	_
31-26	4770-4776	states	_
31-27	4777-4778	.	_

32-1	4779-4786	Alcohol	_
32-2	4787-4790	and	_
32-3	4791-4797	stress	_
32-4	4798-4805	scripts	_
32-5	4806-4814	relative	_
32-6	4815-4817	to	_
32-7	4818-4825	neutral	_
32-8	4826-4830	have	_
32-9	4831-4841	previously	_
32-10	4842-4846	been	_
32-11	4847-4852	shown	_
32-12	4853-4855	to	_
32-13	4856-4864	increase	_
32-14	4865-4872	craving	_
32-15	4873-4874	,	_
32-16	4875-4882	anxiety	_
32-17	4883-4884	,	_
32-18	4885-4890	heart	_
32-19	4891-4895	rate	_
32-20	4896-4899	and	_
32-21	4900-4908	cortisol	_
32-22	4909-4915	levels	_
32-23	4916-4917	.	_

33-1	4918-4922	Each	_
33-2	4923-4928	2-min	_
33-3	4929-4935	script	_
33-4	4936-4939	was	_
33-5	4940-4945	based	_
33-6	4946-4948	on	_
33-7	4949-4950	a	_
33-8	4951-4959	personal	_
33-9	4960-4970	experience	_
33-10	4971-4980	described	_
33-11	4981-4983	by	_
33-12	4984-4987	the	_
33-13	4988-4999	participant	_
33-14	5000-5003	and	_
33-15	5004-5014	audiotaped	_
33-16	5015-5018	for	_
33-17	5019-5031	presentation	_
33-18	5032-5038	during	_
33-19	5039-5047	scanning	_
33-20	5048-5055	session	_
33-21	5056-5057	(	_
33-22	5058-5061	see	_
33-23	5062-5074	Supplemental	_
33-24	5075-5083	material	_
33-25	5084-5087	for	_
33-26	5088-5095	further	_
33-27	5096-5107	information	_
33-28	5108-5109	)	_
33-29	5110-5111	.	_

34-1	5112-5115	Six	_
34-2	5116-5120	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-3	5121-5127	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-4	5128-5129	(	_
34-5	5130-5131	2	_
34-6	5132-5135	per	_
34-7	5136-5145	condition	_
34-8	5146-5147	)	_
34-9	5148-5152	were	_
34-10	5153-5161	acquired	_
34-11	5162-5167	using	_
34-12	5168-5169	a	_
34-13	5170-5175	block	_
34-14	5176-5182	design	_
34-15	5183-5184	.	_

35-1	5185-5188	The	_
35-2	5189-5194	order	_
35-3	5195-5197	of	_
35-4	5198-5201	the	_
35-5	5202-5203	3	_
35-6	5204-5210	script	_
35-7	5211-5221	conditions	_
35-8	5222-5226	were	_
35-9	5227-5237	randomized	_
35-10	5238-5241	and	_
35-11	5242-5257	counterbalanced	_
35-12	5258-5264	across	_
35-13	5265-5277	participants	_
35-14	5278-5279	.	_

36-1	5280-5284	Each	_
36-2	5285-5291	script	_
36-3	5292-5295	was	_
36-4	5296-5305	presented	_
36-5	5306-5310	only	_
36-6	5311-5315	once	_
36-7	5316-5319	for	_
36-8	5320-5324	each	_
36-9	5325-5336	participant	_
36-10	5337-5338	,	_
36-11	5339-5342	and	_
36-12	5343-5350	scripts	_
36-13	5351-5353	of	_
36-14	5354-5357	the	_
36-15	5358-5362	same	_
36-16	5363-5372	condition	_
36-17	5373-5377	were	_
36-18	5378-5381	not	_
36-19	5382-5391	presented	_
36-20	5392-5405	consecutively	_
36-21	5406-5407	.	_

37-1	5408-5412	Each	_
37-2	5413-5418	trial	_
37-3	5419-5425	lasted	_
37-4	5426-5427	5	_
37-5	5428-5431	min	_
37-6	5432-5433	,	_
37-7	5434-5443	including	_
37-8	5444-5445	a	_
37-9	5446-5453	1.5-min	_
37-10	5454-5459	quiet	_
37-11	5460-5468	baseline	_
37-12	5469-5475	period	_
37-13	5476-5484	followed	_
37-14	5485-5487	by	_
37-15	5488-5489	a	_
37-16	5490-5500	continuous	_
37-17	5501-5508	2.5-min	_
37-18	5509-5516	imagery	_
37-19	5517-5523	period	_
37-20	5524-5525	(	_
37-21	5526-5531	2-min	_
37-22	5532-5536	read	_
37-23	5537-5544	imagery	_
37-24	5545-5546	,	_
37-25	5547-5554	0.5-min	_
37-26	5555-5560	quiet	_
37-27	5561-5568	imagery	_
37-28	5569-5570	)	_
37-29	5571-5574	and	_
37-30	5575-5576	a	_
37-31	5577-5582	1-min	_
37-32	5583-5588	quiet	_
37-33	5589-5597	recovery	_
37-34	5598-5599	.	_

38-1	5600-5606	During	_
38-2	5607-5615	baseline	_
38-3	5616-5617	,	_
38-4	5618-5630	participants	_
38-5	5631-5635	were	_
38-6	5636-5646	instructed	_
38-7	5647-5649	to	_
38-8	5650-5654	stay	_
38-9	5655-5660	still	_
38-10	5661-5663	in	_
38-11	5664-5667	the	_
38-12	5668-5675	scanner	_
38-13	5676-5683	without	_
38-14	5684-5692	engaging	_
38-15	5693-5695	in	_
38-16	5696-5699	any	_
38-17	5700-5706	mental	_
38-18	5707-5715	activity	_
38-19	5716-5717	.	_

39-1	5718-5720	To	_
39-2	5721-5729	minimize	_
39-3	5730-5738	residual	_
39-4	5739-5754	craving/anxiety	_
39-5	5755-5762	between	_
39-6	5763-5769	trials	_
39-7	5770-5771	,	_
39-8	5772-5775	all	_
39-9	5776-5784	subjects	_
39-10	5785-5789	were	_
39-11	5790-5795	asked	_
39-12	5796-5798	to	_
39-13	5799-5807	practice	_
39-14	5808-5813	2-min	_
39-15	5814-5825	progressive	_
39-16	5826-5836	relaxation	_
39-17	5837-5838	.	_

40-1	5839-5844	After	_
40-2	5845-5855	relaxation	_
40-3	5856-5857	,	_
40-4	5858-5861	all	_
40-5	5862-5874	participants	_
40-6	5875-5883	returned	_
40-7	5884-5886	to	_
40-8	5887-5895	baseline	_
40-9	5896-5902	levels	_
40-10	5903-5905	of	_
40-11	5906-5916	subjective	_
40-12	5917-5924	craving	_
40-13	5925-5928	and	_
40-14	5929-5936	anxiety	_
40-15	5937-5944	ratings	_
40-16	5945-5946	,	_
40-17	5947-5953	before	_
40-18	5954-5962	starting	_
40-19	5963-5966	the	_
40-20	5967-5971	next	_
40-21	5972-5975	cue	_
40-22	5976-5981	trial	_
40-23	5982-5983	,	_
40-24	5984-5992	verified	_
40-25	5993-5995	by	_
40-26	5996-5998	no	_
40-27	5999-6010	statistical	_
40-28	6011-6021	difference	_
40-29	6022-6024	in	_
40-30	6025-6033	baseline	_
40-31	6034-6041	ratings	_
40-32	6042-6048	across	_
40-33	6049-6055	trials	_
40-34	6056-6057	.	_

41-1	6058-6070	Connectivity	_
41-2	6071-6084	preprocessing	_
41-3	6085-6091	Images	_
41-4	6092-6096	were	_
41-5	6097-6107	slice-time	_
41-6	6108-6111	and	_
41-7	6112-6118	motion	_
41-8	6119-6128	corrected	_
41-9	6129-6134	using	_
41-10	6135-6139	SPM5	_
41-11	6140-6141	(	_
41-12	6142-6146	http	_
41-13	6147-6148	:	_
41-14	6149-6172	//www.fil.ion.ucl.ac.uk	_
41-15	6173-6174	)	_
41-16	6175-6176	.	_

42-1	6177-6183	Images	_
42-2	6184-6188	were	_
42-3	6189-6200	iteratively	_
42-4	6201-6209	smoothed	_
42-5	6210-6215	until	_
42-6	6216-6219	the	_
42-7	6220-6230	smoothness	_
42-8	6231-6234	for	_
42-9	6235-6238	any	_
42-10	6239-6244	image	_
42-11	6245-6248	had	_
42-12	6249-6250	a	_
42-13	6251-6255	full	_
42-14	6256-6261	width	_
42-15	6262-6266	half	_
42-16	6267-6274	maximum	_
42-17	6275-6277	of	_
42-18	6278-6291	approximately	_
42-19	6292-6293	6	_
42-20	6294-6296	mm	_
42-21	6297-6298	.	_

43-1	6299-6303	This	_
43-2	6304-6313	iterative	_
43-3	6314-6323	smoothing	_
43-4	6324-6327	has	_
43-5	6328-6332	been	_
43-6	6333-6338	shown	_
43-7	6339-6341	to	_
43-8	6342-6350	minimize	_
43-9	6351-6357	motion	_
43-10	6358-6367	confounds	_
43-11	6368-6378	associated	_
43-12	6379-6383	with	_
43-13	6384-6397	resting-state	_
43-14	6398-6402	fMRI	_
43-15	6403-6404	.	_

44-1	6405-6408	All	_
44-2	6409-6416	further	_
44-3	6417-6425	analysis	_
44-4	6426-6429	was	_
44-5	6430-6439	performed	_
44-6	6440-6445	using	_
44-7	6446-6454	BioImage	_
44-8	6455-6460	Suite	_
44-9	6461-6467	unless	_
44-10	6468-6477	otherwise	_
44-11	6478-6487	specified	_
44-12	6488-6489	.	_

45-1	6490-6494	Runs	_
45-2	6495-6499	were	_
45-3	6500-6507	further	_
45-4	6508-6520	preprocessed	_
45-5	6521-6533	individually	_
45-6	6534-6537	for	_
45-7	6538-6550	connectivity	_
45-8	6551-6559	analysis	_
45-9	6560-6561	.	_

46-1	6562-6569	Several	_
46-2	6570-6580	covariates	_
46-3	6581-6583	of	_
46-4	6584-6586	no	_
46-5	6587-6595	interest	_
46-6	6596-6600	were	_
46-7	6601-6610	regressed	_
46-8	6611-6615	from	_
46-9	6616-6619	the	_
46-10	6620-6624	data	_
46-11	6625-6634	including	_
46-12	6635-6641	linear	_
46-13	6642-6645	and	_
46-14	6646-6655	quadratic	_
46-15	6656-6661	drift	_
46-16	6662-6663	,	_
46-17	6664-6667	six	_
46-18	6668-6678	rigid-body	_
46-19	6679-6685	motion	_
46-20	6686-6696	parameters	_
46-21	6697-6698	,	_
46-22	6699-6703	mean	_
46-23	6704-6719	cerebral-spinal	_
46-24	6720-6725	fluid	_
46-25	6726-6727	(	_
46-26	6728-6731	CSF	_
46-27	6732-6733	)	_
46-28	6734-6740	signal	_
46-29	6741-6742	,	_
46-30	6743-6747	mean	_
46-31	6748-6753	white	_
46-32	6754-6760	matter	_
46-33	6761-6767	signal	_
46-34	6768-6769	,	_
46-35	6770-6773	and	_
46-36	6774-6778	mean	_
46-37	6779-6785	global	_
46-38	6786-6792	signal	_
46-39	6793-6794	.	_

47-1	6795-6802	Finally	_
47-2	6803-6804	,	_
47-3	6805-6808	the	_
47-4	6809-6813	data	_
47-5	6814-6818	were	_
47-6	6819-6829	temporally	_
47-7	6830-6838	smoothed	_
47-8	6839-6843	with	_
47-9	6844-6845	a	_
47-10	6846-6850	zero	_
47-11	6851-6855	mean	_
47-12	6856-6860	unit	_
47-13	6861-6869	variance	_
47-14	6870-6878	Gaussian	_
47-15	6879-6885	filter	_
47-16	6886-6887	(	_
47-17	6888-6894	cutoff	_
47-18	6895-6904	frequency	_
47-19	6905-6906	=	_
47-20	6907-6911	0.12	_
47-21	6912-6914	Hz	_
47-22	6915-6916	)	_
47-23	6917-6918	.	_

48-1	6919-6920	A	_
48-2	6921-6925	gray	_
48-3	6926-6932	matter	_
48-4	6933-6937	mask	_
48-5	6938-6941	was	_
48-6	6942-6949	applied	_
48-7	6950-6952	to	_
48-8	6953-6956	the	_
48-9	6957-6961	data	_
48-10	6962-6964	so	_
48-11	6965-6969	that	_
48-12	6970-6974	only	_
48-13	6975-6981	voxels	_
48-14	6982-6984	in	_
48-15	6985-6988	the	_
48-16	6989-6993	gray	_
48-17	6994-7000	matter	_
48-18	7001-7005	were	_
48-19	7006-7010	used	_
48-20	7011-7013	in	_
48-21	7014-7017	the	_
48-22	7018-7029	calculation	_
48-23	7030-7031	.	_

49-1	7032-7039	Finally	_
49-2	7040-7041	,	_
49-3	7042-7045	for	_
49-4	7046-7050	each	_
49-5	7051-7056	voxel	_
49-6	7057-7058	,	_
49-7	7059-7063	time	_
49-8	7064-7071	courses	_
49-9	7072-7076	were	_
49-10	7077-7087	normalized	_
49-11	7088-7090	by	_
49-12	7091-7099	removing	_
49-13	7100-7104	that	_
49-14	7105-7109	time	_
49-15	7110-7116	course	_
49-16	7117-7119	's	_
49-17	7120-7124	mean	_
49-18	7125-7128	and	_
49-19	7129-7137	dividing	_
49-20	7138-7140	by	_
49-21	7141-7145	that	_
49-22	7146-7150	time	_
49-23	7151-7157	course	_
49-24	7158-7160	's	_
49-25	7161-7169	standard	_
49-26	7170-7179	deviation	_
49-27	7180-7181	.	_

50-1	7182-7184	As	_
50-2	7185-7195	previously	_
50-3	7196-7205	described	_
50-4	7206-7207	,	_
50-5	7208-7220	connectivity	_
50-6	7221-7229	analysis	_
50-7	7230-7233	was	_
50-8	7234-7238	only	_
50-9	7239-7248	performed	_
50-10	7249-7251	on	_
50-11	7252-7255	the	_
50-12	7256-7266	continuous	_
50-13	7267-7274	2.5-min	_
50-14	7275-7282	imagery	_
50-15	7283-7289	period	_
50-16	7290-7291	.	_

51-1	7292-7295	The	_
51-2	7296-7301	2-min	_
51-3	7302-7308	active	_
51-4	7309-7316	imagery	_
51-5	7317-7323	period	_
51-6	7324-7327	and	_
51-7	7328-7335	0.5-min	_
51-8	7336-7343	passive	_
51-9	7344-7351	imagery	_
51-10	7352-7358	period	_
51-11	7359-7363	were	_
51-12	7364-7373	extracted	_
51-13	7374-7378	from	_
51-14	7379-7382	the	_
51-15	7383-7387	full	_
51-16	7388-7395	dataset	_
51-17	7396-7399	and	_
51-18	7400-7407	imagery	_
51-19	7408-7415	periods	_
51-20	7416-7418	of	_
51-21	7419-7422	the	_
51-22	7423-7427	same	_
51-23	7428-7431	cue	_
51-24	7432-7437	trial	_
51-25	7438-7442	were	_
51-26	7443-7455	concatenated	_
51-27	7456-7459	for	_
51-28	7460-7467	further	_
51-29	7468-7476	analysis	_
51-30	7477-7478	,	_
51-31	7479-7488	resulting	_
51-32	7489-7491	in	_
51-33	7492-7505	approximately	_
51-34	7506-7507	5	_
51-35	7508-7511	min	_
51-36	7512-7514	of	_
51-37	7515-7519	data	_
51-38	7520-7523	for	_
51-39	7524-7528	each	_
51-40	7529-7532	cue	_
51-41	7533-7542	condition	_
51-42	7543-7544	.	_

52-1	7545-7548	The	_
52-2	7549-7554	large	_
52-3	7555-7561	amount	_
52-4	7562-7564	of	_
52-5	7565-7575	continuous	_
52-6	7576-7580	task	_
52-7	7581-7585	data	_
52-8	7586-7592	allows	_
52-9	7593-7595	us	_
52-10	7596-7598	to	_
52-11	7599-7602	use	_
52-12	7603-7608	novel	_
52-13	7609-7620	data-driven	_
52-14	7621-7633	connectivity	_
52-15	7634-7641	methods	_
52-16	7642-7649	usually	_
52-17	7650-7658	reserved	_
52-18	7659-7662	for	_
52-19	7663-7676	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-20	7677-7681	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
52-21	7682-7683	.	_

53-1	7684-7692	Standard	_
53-2	7693-7698	block	_
53-3	7699-7705	design	_
53-4	7706-7711	tasks	_
53-5	7712-7716	with	_
53-6	7717-7718	~	_
53-7	7719-7721	30	_
53-8	7722-7723	s	_
53-9	7724-7730	blocks	_
53-10	7731-7733	or	_
53-11	7734-7747	event-related	_
53-12	7748-7754	design	_
53-13	7755-7760	tasks	_
53-14	7761-7766	would	_
53-15	7767-7770	not	_
53-16	7771-7778	provide	_
53-17	7779-7780	a	_
53-18	7781-7791	sufficient	_
53-19	7792-7798	amount	_
53-20	7799-7801	of	_
53-21	7802-7812	continuous	_
53-22	7813-7817	data	_
53-23	7818-7821	for	_
53-24	7822-7826	such	_
53-25	7827-7834	methods	_
53-26	7835-7836	.	_

54-1	7837-7839	As	_
54-2	7840-7844	each	_
54-3	7845-7848	run	_
54-4	7849-7852	was	_
54-5	7853-7865	individually	_
54-6	7866-7875	processed	_
54-7	7876-7879	and	_
54-8	7880-7890	normalized	_
54-9	7891-7892	,	_
54-10	7893-7906	concatenating	_
54-11	7907-7911	runs	_
54-12	7912-7914	as	_
54-13	7915-7918	the	_
54-14	7919-7923	same	_
54-15	7924-7927	cue	_
54-16	7928-7934	trials	_
54-17	7935-7938	and	_
54-18	7939-7949	performing	_
54-19	7950-7961	correlation	_
54-20	7962-7970	analysis	_
54-21	7971-7973	is	_
54-22	7974-7977	the	_
54-23	7978-7988	equivalent	_
54-24	7989-7991	of	_
54-25	7992-8002	performing	_
54-26	8003-8014	correlation	_
54-27	8015-8023	analysis	_
54-28	8024-8027	for	_
54-29	8028-8032	each	_
54-30	8033-8045	individually	_
54-31	8046-8049	and	_
54-32	8050-8059	averaging	_
54-33	8060-8063	the	_
54-34	8064-8073	resulting	_
54-35	8074-8085	correlation	_
54-36	8086-8087	.	_

55-1	8088-8091	ICD	_
55-2	8092-8104	connectivity	_
55-3	8105-8107	To	_
55-4	8108-8119	investigate	_
55-5	8120-8123	cue	_
55-6	8124-8131	related	_
55-7	8132-8143	differences	_
55-8	8144-8146	in	_
55-9	8147-8159	connectivity	_
55-10	8160-8167	between	_
55-11	8168-8171	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
55-12	8172-8180	patients	_
55-13	8181-8182	,	_
55-14	8183-8195	connectivity	_
55-15	8196-8198	of	_
55-16	8199-8203	each	_
55-17	8204-8209	voxel	_
55-18	8210-8212	as	_
55-19	8213-8221	measured	_
55-20	8222-8224	by	_
55-21	8225-8228	the	_
55-22	8229-8238	intrinsic	_
55-23	8239-8251	connectivity	_
55-24	8252-8264	distribution	_
55-25	8265-8266	(	_
55-26	8267-8270	ICD	_
55-27	8271-8272	)	_
55-28	8273-8276	was	_
55-29	8277-8287	calculated	_
55-30	8288-8291	for	_
55-31	8292-8296	each	_
55-32	8297-8307	individual	_
55-33	8308-8319	participant	_
55-34	8320-8322	as	_
55-35	8323-8332	described	_
55-36	8333-8343	previously	_
55-37	8344-8345	.	_

56-1	8346-8349	ICD	_
56-2	8350-8360	represents	_
56-3	8361-8362	a	_
56-4	8363-8377	generalization	_
56-5	8378-8380	of	_
56-6	8381-8384	the	_
56-7	8385-8392	network	_
56-8	8393-8399	theory	_
56-9	8400-8407	measure	_
56-10	8408-8410	of	_
56-11	8411-8417	degree	_
56-12	8418-8419	.	_

57-1	8420-8422	In	_
57-2	8423-8426	the	_
57-3	8427-8434	context	_
57-4	8435-8437	of	_
57-5	8438-8450	neuroimaging	_
57-6	8451-8452	,	_
57-7	8453-8459	degree	_
57-8	8460-8468	involves	_
57-9	8469-8480	correlating	_
57-10	8481-8484	the	_
57-11	8485-8489	time	_
57-12	8490-8496	course	_
57-13	8497-8500	for	_
57-14	8501-8504	any	_
57-15	8505-8510	voxel	_
57-16	8511-8515	with	_
57-17	8516-8521	every	_
57-18	8522-8527	other	_
57-19	8528-8533	voxel	_
57-20	8534-8538	time	_
57-21	8539-8545	course	_
57-22	8546-8548	in	_
57-23	8549-8552	the	_
57-24	8553-8558	brain	_
57-25	8559-8562	and	_
57-26	8563-8565	is	_
57-27	8566-8573	defined	_
57-28	8574-8576	as	_
57-29	8577-8580	the	_
57-30	8581-8587	number	_
57-31	8588-8590	of	_
57-32	8591-8602	connections	_
57-33	8603-8605	to	_
57-34	8606-8610	that	_
57-35	8611-8616	voxel	_
57-36	8617-8621	with	_
57-37	8622-8634	correlations	_
57-38	8635-8642	greater	_
57-39	8643-8647	than	_
57-40	8648-8650	an	_
57-41	8651-8660	arbitrary	_
57-42	8661-8670	threshold	_
57-43	8671-8672	.	_

58-1	8673-8676	ICD	_
58-2	8677-8687	calculates	_
58-3	8688-8694	degree	_
58-4	8695-8699	over	_
58-5	8700-8703	all	_
58-6	8704-8712	possible	_
58-7	8713-8722	arbitrary	_
58-8	8723-8733	thresholds	_
58-9	8734-8737	and	_
58-10	8738-8742	then	_
58-11	8743-8749	models	_
58-12	8750-8753	the	_
58-13	8754-8760	change	_
58-14	8761-8763	in	_
58-15	8764-8770	degree	_
58-16	8771-8773	as	_
58-17	8774-8777	the	_
58-18	8778-8787	threshold	_
58-19	8788-8790	is	_
58-20	8791-8800	increased	_
58-21	8801-8802	.	_

59-1	8803-8805	By	_
59-2	8806-8815	examining	_
59-3	8816-8819	all	_
59-4	8820-8828	possible	_
59-5	8829-8838	arbitrary	_
59-6	8839-8849	thresholds	_
59-7	8850-8851	,	_
59-8	8852-8855	ICD	_
59-9	8856-8858	is	_
59-10	8859-8862	not	_
59-11	8863-8872	dependent	_
59-12	8873-8875	on	_
59-13	8876-8877	a	_
59-14	8878-8884	single	_
59-15	8885-8894	threshold	_
59-16	8895-8898	and	_
59-17	8899-8909	eliminates	_
59-18	8910-8913	the	_
59-19	8914-8918	need	_
59-20	8919-8921	to	_
59-21	8922-8929	specify	_
59-22	8930-8932	an	_
59-23	8933-8942	arbitrary	_
59-24	8943-8952	threshold	_
59-25	8953-8954	.	_

60-1	8955-8967	Specifically	_
60-2	8968-8969	,	_
60-3	8970-8973	for	_
60-4	8974-8977	the	_
60-5	8978-8985	current	_
60-6	8986-8991	voxel	_
60-7	8992-8993	,	_
60-8	8994-8995	a	_
60-9	8996-9005	histogram	_
60-10	9006-9008	of	_
60-11	9009-9012	all	_
60-12	9013-9016	the	_
60-13	9017-9021	time	_
60-14	9022-9028	series	_
60-15	9029-9041	correlations	_
60-16	9042-9044	to	_
60-17	9045-9049	that	_
60-18	9050-9055	voxel	_
60-19	9056-9059	was	_
60-20	9060-9071	constructed	_
60-21	9072-9074	to	_
60-22	9075-9083	estimate	_
60-23	9084-9087	the	_
60-24	9088-9100	distribution	_
60-25	9101-9103	of	_
60-26	9104-9114	functional	_
60-27	9115-9127	connectivity	_
60-28	9128-9130	to	_
60-29	9131-9135	that	_
60-30	9136-9141	voxel	_
60-31	9142-9143	.	_

61-1	9144-9148	This	_
61-2	9149-9161	distribution	_
61-3	9162-9164	of	_
61-4	9165-9177	connectivity	_
61-5	9178-9181	was	_
61-6	9182-9191	converted	_
61-7	9192-9194	to	_
61-8	9195-9196	a	_
61-9	9197-9205	survival	_
61-10	9206-9214	function	_
61-11	9215-9218	and	_
61-12	9219-9222	the	_
61-13	9223-9231	survival	_
61-14	9232-9240	function	_
61-15	9241-9244	was	_
61-16	9245-9251	fitted	_
61-17	9252-9256	with	_
61-18	9257-9258	a	_
61-19	9259-9268	stretched	_
61-20	9269-9280	exponential	_
61-21	9281-9285	with	_
61-22	9286-9293	unknown	_
61-23	9294-9302	variance	_
61-24	9303-9304	,	_
61-25	9305-9306	α	_
61-26	9307-9308	.	_

62-1	9309-9311	As	_
62-2	9312-9317	alpha	_
62-3	9318-9326	controls	_
62-4	9327-9330	the	_
62-5	9331-9337	spread	_
62-6	9338-9340	of	_
62-7	9341-9344	the	_
62-8	9345-9357	distribution	_
62-9	9358-9360	of	_
62-10	9361-9372	connections	_
62-11	9373-9374	,	_
62-12	9375-9376	a	_
62-13	9377-9383	larger	_
62-14	9384-9389	alpha	_
62-15	9390-9399	indicates	_
62-16	9400-9401	a	_
62-17	9402-9409	greater	_
62-18	9410-9416	number	_
62-19	9417-9419	of	_
62-20	9420-9424	high	_
62-21	9425-9436	correlation	_
62-22	9437-9448	connections	_
62-23	9449-9450	.	_

63-1	9451-9458	Finally	_
63-2	9459-9460	,	_
63-3	9461-9465	this	_
63-4	9466-9473	process	_
63-5	9474-9476	is	_
63-6	9477-9485	repeated	_
63-7	9486-9489	for	_
63-8	9490-9493	all	_
63-9	9494-9500	voxels	_
63-10	9501-9503	in	_
63-11	9504-9507	the	_
63-12	9508-9512	gray	_
63-13	9513-9519	matter	_
63-14	9520-9529	resulting	_
63-15	9530-9532	in	_
63-16	9533-9534	a	_
63-17	9535-9545	parametric	_
63-18	9546-9551	image	_
63-19	9552-9554	of	_
63-20	9555-9558	the	_
63-21	9559-9564	alpha	_
63-22	9565-9574	parameter	_
63-23	9575-9578	for	_
63-24	9579-9583	each	_
63-25	9584-9595	participant	_
63-26	9596-9597	.	_

64-1	9598-9610	Additionally	_
64-2	9611-9612	,	_
64-3	9613-9617	each	_
64-4	9618-9621	ICD	_
64-5	9622-9625	map	_
64-6	9626-9629	was	_
64-7	9630-9640	normalized	_
64-8	9641-9643	by	_
64-9	9644-9655	subtracting	_
64-10	9656-9659	the	_
64-11	9660-9664	mean	_
64-12	9665-9671	across	_
64-13	9672-9675	all	_
64-14	9676-9682	voxels	_
64-15	9683-9686	and	_
64-16	9687-9695	dividing	_
64-17	9696-9698	by	_
64-18	9699-9702	the	_
64-19	9703-9711	standard	_
64-20	9712-9721	deviation	_
64-21	9722-9728	across	_
64-22	9729-9732	all	_
64-23	9733-9739	voxels	_
64-24	9740-9741	.	_

65-1	9742-9746	This	_
65-2	9747-9759	z-score-like	_
65-3	9760-9773	normalization	_
65-4	9774-9778	does	_
65-5	9779-9782	not	_
65-6	9783-9789	change	_
65-7	9790-9793	the	_
65-8	9794-9804	underlying	_
65-9	9805-9815	topography	_
65-10	9816-9818	of	_
65-11	9819-9831	connectivity	_
65-12	9832-9839	pattern	_
65-13	9840-9843	but	_
65-14	9844-9850	allows	_
65-15	9851-9854	for	_
65-16	9855-9859	each	_
65-17	9860-9863	map	_
65-18	9864-9866	to	_
65-19	9867-9869	be	_
65-20	9870-9880	comparably	_
65-21	9881-9887	scaled	_
65-22	9888-9894	across	_
65-23	9895-9907	participants	_
65-24	9908-9909	.	_

66-1	9910-9921	Statistical	_
66-2	9922-9930	analysis	_
66-3	9931-9934	ICD	_
66-4	9935-9947	connectivity	_
66-5	9948-9952	maps	_
66-6	9953-9957	were	_
66-7	9958-9964	warped	_
66-8	9965-9969	into	_
66-9	9970-9976	common	_
66-10	9977-9982	space	_
66-11	9983-9984	(	_
66-12	9985-9988	see	_
66-13	9989-10001	Supplemental	_
66-14	10002-10010	material	_
66-15	10011-10012	)	_
66-16	10013-10016	and	_
66-17	10017-10025	analyzed	_
66-18	10026-10031	using	_
66-19	10032-10042	voxel-wise	_
66-20	10043-10049	random	_
66-21	10050-10057	effects	_
66-22	10058-10065	general	_
66-23	10066-10072	linear	_
66-24	10073-10081	modeling	_
66-25	10082-10086	with	_
66-26	10087-10092	group	_
66-27	10093-10100	modeled	_
66-28	10101-10103	as	_
66-29	10104-10105	a	_
66-30	10106-10113	between	_
66-31	10114-10121	subject	_
66-32	10122-10128	factor	_
66-33	10129-10130	,	_
66-34	10131-10134	cue	_
66-35	10135-10145	conditions	_
66-36	10146-10153	modeled	_
66-37	10154-10156	as	_
66-38	10157-10163	within	_
66-39	10164-10171	subject	_
66-40	10172-10179	factors	_
66-41	10180-10181	,	_
66-42	10182-10185	and	_
66-43	10186-10194	subjects	_
66-44	10195-10197	as	_
66-45	10198-10204	random	_
66-46	10205-10212	factors	_
66-47	10213-10218	using	_
66-48	10219-10224	3dLME	_
66-49	10225-10226	.	_

67-1	10227-10234	Imaging	_
67-2	10235-10242	results	_
67-3	10243-10246	are	_
67-4	10247-10252	shown	_
67-5	10253-10255	at	_
67-6	10256-10257	a	_
67-7	10258-10271	cluster-level	_
67-8	10272-10281	threshold	_
67-9	10282-10284	of	_
67-10	10285-10286	p	_
67-11	10287-10288	<	_
67-12	10289-10293	0.05	_
67-13	10294-10305	family-wise	_
67-14	10306-10311	error	_
67-15	10312-10313	(	_
67-16	10314-10317	FWE	_
67-17	10318-10319	)	_
67-18	10320-10330	correction	_
67-19	10331-10333	as	_
67-20	10334-10344	determined	_
67-21	10345-10347	by	_
67-22	10348-10352	AFNI	_
67-23	10353-10355	's	_
67-24	10356-10366	3dClustSim	_
67-25	10367-10374	program	_
67-26	10375-10376	(	_
67-27	10377-10384	version	_
67-28	10385-10392	16.0.09	_
67-29	10393-10394	)	_
67-30	10395-10400	using	_
67-31	10401-10402	a	_
67-32	10403-10410	cluster	_
67-33	10411-10418	forming	_
67-34	10419-10428	threshold	_
67-35	10429-10431	of	_
67-36	10432-10433	p	_
67-37	10434-10435	=	_
67-38	10436-10441	0.001	_
67-39	10442-10443	,	_
67-40	10444-10450	10,000	_
67-41	10451-10461	iterations	_
67-42	10462-10463	,	_
67-43	10464-10465	a	_
67-44	10466-10470	grey	_
67-45	10471-10477	matter	_
67-46	10478-10482	mask	_
67-47	10483-10484	,	_
67-48	10485-10488	and	_
67-49	10489-10490	a	_
67-50	10491-10501	smoothness	_
67-51	10502-10511	estimated	_
67-52	10512-10517	using	_
67-53	10518-10525	3dFWHMx	_
67-54	10526-10530	with	_
67-55	10531-10534	the	_
67-56	10535-10539	–ACF	_
67-57	10540-10546	option	_
67-58	10547-10548	.	_

68-1	10549-10558	Follow-up	_
68-2	10559-10563	seed	_
68-3	10564-10572	analyses	_
68-4	10573-10577	were	_
68-5	10578-10583	based	_
68-6	10584-10586	on	_
68-7	10587-10590	the	_
68-8	10591-10594	ICD	_
68-9	10595-10607	connectivity	_
68-10	10608-10615	defined	_
68-11	10616-10623	regions	_
68-12	10624-10626	of	_
68-13	10627-10635	interest	_
68-14	10636-10637	.	_

69-1	10638-10648	Anatomical	_
69-2	10649-10658	locations	_
69-3	10659-10663	were	_
69-4	10664-10673	localized	_
69-5	10674-10679	using	_
69-6	10680-10683	the	_
69-7	10684-10688	Yale	_
69-8	10689-10697	Brodmann	_
69-9	10698-10703	Atlas	_
69-10	10704-10705	.	_

70-1	10706-10714	Analysis	_
70-2	10715-10717	of	_
70-3	10718-10725	between	_
70-4	10726-10731	group	_
70-5	10732-10738	motion	_
70-6	10739-10742	and	_
70-7	10743-10750	methods	_
70-8	10751-10755	used	_
70-9	10756-10758	to	_
70-10	10759-10767	minimize	_
70-11	10768-10774	motion	_
70-12	10775-10782	related	_
70-13	10783-10792	confounds	_
70-14	10793-10796	can	_
70-15	10797-10799	be	_
70-16	10800-10805	found	_
70-17	10806-10808	in	_
70-18	10809-10821	Supplemental	_
70-19	10822-10830	material	_
70-20	10831-10832	.	_

71-1	10833-10841	Analysis	_
71-2	10842-10844	of	_
71-3	10845-10856	non-imaging	_
71-4	10857-10861	data	_
71-5	10862-10865	was	_
71-6	10866-10875	performed	_
71-7	10876-10878	in	_
71-8	10879-10881	R.	_
71-9	10882-10893	Prospective	_
71-10	10894-10898	time	_
71-11	10899-10901	to	_
71-12	10902-10909	relapse	_
71-13	10910-10918	analysis	_
71-14	10919-10926	Relapse	_
71-15	10927-10930	was	_
71-16	10931-10939	assessed	_
71-17	10940-10953	prospectively	_
71-18	10954-10956	in	_
71-19	10957-10960	the	_
71-20	10961-10963	90	_
71-21	10964-10968	days	_
71-22	10969-10974	after	_
71-23	10975-10985	completion	_
71-24	10986-10988	of	_
71-25	10989-10998	inpatient	_
71-26	10999-11008	treatment	_
71-27	11009-11010	.	_

72-1	11011-11014	The	_
72-2	11015-11020	first	_
72-3	11021-11024	day	_
72-4	11025-11027	of	_
72-5	11028-11034	return	_
72-6	11035-11037	to	_
72-7	11038-11045	alcohol	_
72-8	11046-11049	use	_
72-9	11050-11056	during	_
72-10	11057-11061	this	_
72-11	11062-11068	90-day	_
72-12	11069-11078	follow-up	_
72-13	11079-11085	period	_
72-14	11086-11088	is	_
72-15	11089-11099	considered	_
72-16	11100-11102	as	_
72-17	11103-11106	the	_
72-18	11107-11113	target	_
72-19	11114-11119	event	_
72-20	11120-11123	and	_
72-21	11124-11127	Cox	_
72-22	11128-11140	proportional	_
72-23	11141-11148	hazards	_
72-24	11149-11159	regression	_
72-25	11160-11161	,	_
72-26	11162-11169	similar	_
72-27	11170-11172	to	_
72-28	11173-11174	a	_
72-29	11175-11188	time-to-event	_
72-30	11189-11197	survival	_
72-31	11198-11206	analyses	_
72-32	11207-11210	was	_
72-33	11211-11220	conducted	_
72-34	11221-11222	,	_
72-35	11223-11225	as	_
72-36	11226-11230	used	_
72-37	11231-11233	in	_
72-38	11234-11237	our	_
72-39	11238-11246	previous	_
72-40	11247-11254	studies	_
72-41	11255-11256	.	_

73-1	11257-11260	Cox	_
73-2	11261-11273	proportional	_
73-3	11274-11280	hazard	_
73-4	11281-11291	regression	_
73-5	11292-11295	was	_
73-6	11296-11305	performed	_
73-7	11306-11308	to	_
73-8	11309-11320	investigate	_
73-9	11321-11328	whether	_
73-10	11329-11341	connectivity	_
73-11	11342-11349	regions	_
73-12	11350-11357	showing	_
73-13	11358-11361	cue	_
73-14	11362-11373	differences	_
73-15	11374-11376	in	_
73-16	11377-11380	AUD	_
73-17	11381-11389	patients	_
73-18	11390-11399	predicted	_
73-19	11400-11403	the	_
73-20	11404-11408	time	_
73-21	11409-11411	to	_
73-22	11412-11417	first	_
73-23	11418-11425	alcohol	_
73-24	11426-11433	relapse	_
73-25	11434-11435	.	_

74-1	11436-11443	Average	_
74-2	11444-11447	ICD	_
74-3	11448-11454	values	_
74-4	11455-11457	of	_
74-5	11458-11466	clusters	_
74-6	11467-11477	identified	_
74-7	11478-11480	in	_
74-8	11481-11484	the	_
74-9	11485-11496	whole-brain	_
74-10	11497-11509	connectivity	_
74-11	11510-11518	analysis	_
74-12	11519-11523	were	_
74-13	11524-11533	extracted	_
74-14	11534-11537	and	_
74-15	11538-11545	entered	_
74-16	11546-11548	as	_
74-17	11549-11560	independent	_
74-18	11561-11570	variables	_
74-19	11571-11572	.	_

75-1	11573-11584	Preliminary	_
75-2	11585-11593	analyses	_
75-3	11594-11603	indicated	_
75-4	11604-11608	that	_
75-5	11609-11614	years	_
75-6	11615-11617	of	_
75-7	11618-11626	nicotine	_
75-8	11627-11634	smoking	_
75-9	11635-11638	and	_
75-10	11639-11644	years	_
75-11	11645-11647	of	_
75-12	11648-11655	alcohol	_
75-13	11656-11659	use	_
75-14	11660-11664	were	_
75-15	11665-11678	significantly	_
75-16	11679-11689	correlated	_
75-17	11690-11691	(	_
75-18	11692-11693	p	_
75-19	11694-11695	<	_
75-20	11696-11700	0.05	_
75-21	11701-11702	)	_
75-22	11703-11707	with	_
75-23	11708-11712	time	_
75-24	11713-11715	to	_
75-25	11716-11723	relapse	_
75-26	11724-11728	such	_
75-27	11729-11733	that	_
75-28	11734-11735	a	_
75-29	11736-11743	greater	_
75-30	11744-11750	number	_
75-31	11751-11753	of	_
75-32	11754-11759	years	_
75-33	11760-11762	of	_
75-34	11763-11770	smoking	_
75-35	11771-11773	or	_
75-36	11774-11781	alcohol	_
75-37	11782-11785	use	_
75-38	11786-11790	were	_
75-39	11791-11801	associated	_
75-40	11802-11806	with	_
75-41	11807-11814	quicker	_
75-42	11815-11822	relapse	_
75-43	11823-11824	.	_

76-1	11825-11829	Thus	_
76-2	11830-11831	,	_
76-3	11832-11837	these	_
76-4	11838-11842	were	_
76-5	11843-11851	included	_
76-6	11852-11854	as	_
76-7	11855-11866	independent	_
76-8	11867-11876	variables	_
76-9	11877-11879	to	_
76-10	11880-11888	evaluate	_
76-11	11889-11894	their	_
76-12	11895-11903	specific	_
76-13	11904-11907	and	_
76-14	11908-11919	independent	_
76-15	11920-11927	effects	_
76-16	11928-11929	.	_

